Catrin Lutz
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (11)
Year:
2026
Year:
2026
Cancer is increasingly recognised as a complex and heterogeneous disease, shaped not only by genetic mutations but also by the physical and biochemical context in which tumours develop. The spatial position of a cell, including its physical, cellular and molecular surroundings, shapes its fate, phenotypic plasticity and potential to transform and drive tumour progression and evolution. Tissue architecture provides a powerful framework for understanding the complex dynamics of cancer. It integrates the structural organisation of the tumour and its surrounding tissue, the distribution of physical forces, biochemical niches, cellular neighbourhoods, and the broader tissue and organ context in which the tumour develops. Together, these elements form a dynamic and evolving landscape that is continuously remodelled through the multiscale communication of cellular, biochemical and mechanical components. Understanding the principles that govern these interactions reveals that cancer is not merely a chaotic aggregation of cells, but a patterned system shaped by coordinated spatial relationships. Here, we discuss the recent literature to examine how physical, biochemical and cellular relationships orchestrate tumour initiation, progression and treatment resistance, and how their collaboration acts not as a passive scaffold, but as the architect of tumour behaviour.
Year:
2026
Genomic alterations affecting components of the fibroblast growth factor (FGF) signaling axis can trigger aberrant pathway activation and tumor development. Genomic truncation of the FGF receptor 2 (FGFR2) exon 18 (E18) disrupts the FGFR2 carboxy-terminal tail (C-tail), acting as a potent driver alteration across multiple tumor types. Here, we analyzed human oncogenomic datasets to reveal that E18 truncations are similarly prevalent in FGFR3, an FGFR2 paralog. FGFR3 E18 truncations primarily occurred due to rearrangements (REs) that involve transforming acidic coiled-coil containing protein 3 (TACC3), resulting in FGFR3ΔE18-TACC3 gene fusions. In contrast to E18-truncated FGFR2, functional in vitro and in vivo examination of Fgfr3 variants demonstrated that the truncation of Fgfr3 E18 is insufficient to promote oncogenic activity in cell lines or in the lungs and mammary glands of mice. Only the combination of an Fgfr3 E18 truncation with a RE partner gene that encodes a receptor-dimerizing domain resulted in the development of tumors, which were sensitive to FGFR inhibition. Overall, these findings suggest that patients with cancers that are positive for rearranged FGFR3 resulting in E18 truncation and a fusion to dimerizing partners should be considered for FGFR-targeted therapies.
Year:
2026
Genetic alterations in receptor tyrosine kinase genes can generate potent oncogenic drivers. Truncation of the FGFR2 gene by its last exon 18 (E18) is caused by structural alterations, such as focal amplifications and gene fusions/rearrangements, as well as by mutations. All the E18-truncating FGFR2 variants (FGFR2ΔE18) act as strong driver alterations in cancer, and they commonly encode a receptor lacking the carboxy (C) terminal tail. In this study, we analyzed a compendium of Fgfr2-E18 variants to uncover the mechanism by which loss of the C-tail renders FGFR2 oncogenic. Although permutation of previously annotated C-terminal FGFR motifs did not recapitulate the tumorigenicity of FGFR2ΔE18, the functional annotation efforts led to the discovery of a C-terminal phenylalanine–serine motif that mediates binding of the C-tail to the kinase domain and thereby suppresses FGFR2 kinase activity. The permutation of this kinase domain–binding and suppression motif in conjunction with other FGFR2-regulatory C-terminal sites fully phenocopied the oncogenic competence of FGFR2ΔE18. Together, these findings delineate how the C-terminal tail prevents FGFR2 from aberrant oncogenic activation. Significance: A C-terminal phenylalanine–serine motif suppresses FGFR2 kinase activity by mediating binding of the C-terminal tail to the kinase domain, explaining how C-terminal truncation activates FGFR2 to promote tumorigenesis.
Year:
2025
Breast cancer is a heterogeneous disease with diverse morphologic and molecular subtypes. Preclinical models that recapitulate the heterogeneity of human breast cancer are needed to advance our fundamental understanding of what makes breast cancer an aggressive disease. To study mechanisms underlying breast cancer progression, we generated orthotopic cell line–derived xenograft (CDX) models from 20 different human breast cancer cell lines using both mammary intraductal injections and fat pad transplantations. The resulting mammary intraductal CDX and fat pad transplantation CDX models covered the full spectrum of disease progression, from in situ disease to metastatic growth. Pathologic analysis revealed two distinct tumor growth morphologies, flat versus nodular, and transcriptomic analysis identified the TGFβ pathway as a potential regulator of these two phenotypes in primary breast cancer. Indeed, knockout of SMAD4 converted nodular-growing tumors to a more confined disease, whereas constitutively active TGFβ receptor I renders lesions more aggressive. This research not only offers insights into the factors driving breast cancer morphology and aggressiveness but also establishes a comprehensive and valuable resource of well-characterized orthotopic CDX models for breast cancer research. Significance: Establishment and investigation of the largest collection of fully characterized breast cancer cell line xenograft models identifies key determinants of tumor morphology and aggressiveness and enables informed preclinical modeling for further research.
Year:
2025
The breast epithelium, vital for mammary gland function, is influenced by oestrogen through the oestrogen receptor (ER) signalling pathway. Luminal breast cancer (BC), characterised by ER expression, comprises the majority of all BCs and presents significant clinical challenges due to therapy resistance and recurrence. Despite advancements in understanding luminal disease, improving long-term survival and reducing relapse of BC patients by predicting therapy efficacy and understanding resistance mechanisms remain critical challenges. This review discusses luminal BC biology, focusing on the molecular classification of primary disease, metastatic spread, and experimental models.
Year:
2025
Proteins identified in Fgfr2-GFP immunoprecipitation samples using MS-based proteomics. The table shows all proteins identified using global proteomics on GFP-immunoprecipitation samples using NMuMG cells expressing GFP, Fgfr2FL-GFP, or Fgfr2DE18- GFP.
Year:
2025
Differentially expressed genes identified in Fgfr2-GFP samples using RNA-seq. The table shows all genes identified using RNA-seq on NMuMG cells expressing GFP, Fgfr2FL-GFP, Fgfr2DE18-GFP, Fgfr2DVFSPD702-6-GFP, or Fgfr2F703A/S704A-GFP.
Year:
2025
Genetic alterations in receptor tyrosine kinase genes can generate potent oncogenic drivers. Truncation of the F GFR 2 gene by its last exon 18 (E18) is caused by structural alterations, such as focal amplifications and gene fusions/rearrangements, as well as by mutations. All the E18-truncating F GFR 2 variants ( F GFR 2 ΔE18 ) act as strong driver alterations in cancer, and they commonly encode a receptor lacking the carboxy (C) terminal tail. In this study, we analyzed a compendium of Fgfr2-E18 variants to uncover the mechanism by which loss of the C-tail renders FGFR2 oncogenic. Although permutation of previously annotated C-terminal FGFR motifs did not recapitulate the tumorigenicity of FGFR2 ΔE18 , the functional annotation efforts led to the discovery of a C-terminal phenylalanine–serine motif that mediates binding of the C-tail to the kinase domain and thereby suppresses FGFR2 kinase activity. The permutation of this kinase domain–binding and suppression motif in conjunction with other FGFR2-regulatory C-terminal sites fully phenocopied the oncogenic competence of FGFR2 ΔE18 . Together, these findings delineate how the C-terminal tail prevents FGFR2 from aberrant oncogenic activation. Significance: A C-terminal phenylalanine–serine motif suppresses FGFR2 kinase activity by mediating binding of the C-terminal tail to the kinase domain, explaining how C-terminal truncation activates FGFR2 to promote tumorigenesis.
Year:
2025
Year:
2025
Collaborators (8)
John Ladbury
Professor and Director of Leeds Centre for Disease Models
University of Leeds
Lodewyk Wessels
Professor
Delft University of Technology
Maarten Altelaar
Professor
Utrecht University
Jelle Wesseling
Professor of Breast Pathology
Leiden University Medical Center
Stefan Prekovic
Group leader
Universitair Medisch Centrum Utrecht
Marieke van de Ven
Head of Mouse Cancer Clinic
-
Violeta Serra
Group Leader
Vall d'Hebron Institute of Oncology
Damir Vareslija
Senior Lecturer and Principal Investigator
RCSI University of Medicine and Health Sciences
Make your next move.
Prepare your application
Review drafts before you send them.